Table 2 53BP1 protein expression level and correlation with clinico-pathological parameters

Age at diagnosis (years)

1

Median (range)

54 (29–75)

≤ 54

80 (52.6%)

40 (52.6%)

40 (52.6%)

> 54

72 (47.4%)

36 (47.4%)

36 (47.5%)

Menopausal status

0.87

Pre-menopausal

69 (44.7%)

34 (44.7%)

35 (46.1%)

Post-menopausal

83 (55.3%)

42 (55.3%)

41 (53.9%)

T classification

0.57

T1

75 (49.3%)

37 (48.7%)

38 (50%)

T2

73 (48%)

38 (50%)

35 (46.1%)

T3-4

4 (2.6%)

1 (1.3%)

3 (3.9%)

N classification

0.015

N0

104 (68.4%)

59 (77.6%)

45 (59.2%)

N+

48 (31.6%)

17 (22.4%)

31 (40.8%)

Histology

0.44

Ductal

117 (77%)

58 (76.4%)

59 (77.6%)

Lobular

9 (5.9%)

3 (3.9%)

6 (7.9%)

Other

26 (17.1%)

15 (19.7%)

11 (14.5%)

Grade

0.46

I / II

1 (0.7%) / 50 (32.9%)

23 (30.3%)

28 (36.8%)

III

101 (66.4%)

53 (69.7%)

48 (63.2%)

ER

0.005

Positive

87 (57.2%)

35 (46.1%)

52 (68.4%)

Negative

65 (42.8%)

41 (53.9%)

24 (31.6%)

PR

0.013

Positive

59 (38.8%)

22 (28.9%)

37 (48.7%)

Negative

93 (61.2%)

54 (71.1%)

39 (51.3%)

HER2

0.73

Positive

48 (31.6%)

25 (32.9%)

23 (30.3%)

Negative

104 (68.4%)

51 (67.1%)

53 (69.7%)

Molecular profile grouping

0.022

HER2+

48 (31.6%)

25 (32.9%)

23 (30.3%)

HR+/HER2-

57 (37.5%)

21 (27.6%)

36 (47.4%)

Triple Negative

47 (30.9%)

30 (39.5%)

17 (22.4%)

BRCA1 methylation Status

0.045

Methylated

18 (11.8%)

13 (17.1%)

5 (6.6%)

Not Methylated

134 (88.2%)

63 (82.9%)

71 (93.4%)

PARP activity

0.048

≤ 2.6 U/mg Prot

39 (25.6%)

21 (27.6%)

18 (23.8%)

2.7 - 7

41 (27%)

27 (35.5%)

14 (18.4%)

7.1 - 14

36 (23.7%)

14 (18.4%)

22 (28.9%)

> 14

36 (23.7%)

14 (18.4%)

22 (28.9%)